Proteome Sciences (PRM) Receives Corporate Rating from FinnCap

FinnCap reissued their corporate rating on shares of Proteome Sciences (LON:PRM) in a research note published on Tuesday.

LON:PRM traded up GBX 0.10 ($0.00) during mid-day trading on Tuesday, reaching GBX 3.50 ($0.05). The stock had a trading volume of 795,573 shares, compared to its average volume of 88,695. Proteome Sciences has a twelve month low of GBX 2.61 ($0.03) and a twelve month high of GBX 5.64 ($0.07).

In other news, insider Martin Diggle bought 500,000 shares of the stock in a transaction that occurred on Monday, August 13th. The shares were acquired at an average cost of GBX 4 ($0.05) per share, for a total transaction of £20,000 ($26,133.54).

About Proteome Sciences

Proteome Sciences plc provides contract research services for the identification, validation, and application of protein biomarkers. It delivers content for personalized medicine in the areas of biomarker services, biomarker assays, isobaric and isotopic reagents, and proprietary biomarkers. The company designs, performs, and interprets high resolution proteomics studies to improve target discovery, validation, and mechanism of action studies; offers specialized services to enhance discovery and validation of mechanistic biomarkers in peripheral fluids; and provides a set of bioinformatics tools to enhance data integration, and select regulated features and map to biological processes.

Recommended Story: How can you know how many shares are floating?

Receive News & Ratings for Proteome Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Proteome Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply